Drug Report History #253853
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v6-EN | Version v3-FR | |
|---|---|---|
| Language (Changed) | Updated to: English | Was: French |
| Date Updated (Changed) | Updated to: 2025-04-02 | Was: 2025-04-01 |
| Drug Identification Number | 02322579 | 02322579 |
| Brand name | SANDOZ FINASTERIDE | SANDOZ FINASTERIDE |
| Common or Proper name | FINASTERIDE | FINASTERIDE |
| Company Name | SANDOZ CANADA INCORPORATED | SANDOZ CANADA INCORPORATED |
| Ingredients | FINASTERIDE | FINASTERIDE |
| Strength(s) | 5MG | 5MG |
| Dosage form(s) | TABLET | TABLET |
| Route of administration | ORAL ORAL | ORAL ORAL |
| Packaging size | 30FCT | 30FCT |
| Additional packaging sizes | ||
| ATC code | G04CB | G04CB |
| ATC description | DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY | DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY |
| Reason for discontinuation (Changed) | Updated to: Manufacturing issues | Was: Business reasons |
| Anticipated discontinuation date | ||
| Actual discontinuation date | 2025-04-01 | 2025-04-01 |
| Remaining supply date | 2025-04-01 | 2025-04-01 |
| Discontinuation status (Changed) | Updated to: Discontinued | Was: To be discontinued |
| Discontinuation decision reversal | no | no |
| Tier 3 Status | No | No |
| Information on remaining supply | ||
| Company comments | ||
| Health Canada comments |